GO
Loading...

Market Outlook

More

  • We are at the start of a "silver market lining," says Jeff Weiss, Tejas Securities Group, charting the market's direction and explaining why he is detecting support levels at the 1240 to 1260 region for the S&P 500.

  • Global Market: Euro Hits Session Low     Tuesday, 5 Jun 2012 | 6:12 AM ET

    CNBC's Kelly Evans reports on all the market moving activity in European markets, including an emergency meeting held today by G7 Finance chiefs on worries about a possible run on Spanish banks.

  • Pre-Market Report: Starbucks Buys Bay Bread     Tuesday, 5 Jun 2012 | 6:00 AM ET

    A look at the U.S. markets ahead of the open, with CNBC's Kelly Evans, including a look at G7 leaders meeting to discuss Europe's growing debt crisis and Starbucks' $100 million acquisition of a bread company.

  • The Dow retreat is part of a new downtrend with initial downside targets near 11,300.

  • Charting Asia | Dow Daily Monday, 4 Jun 2012 | 11:21 PM ET
  • Stifel Nicolaus CEO on US Recovery     Monday, 4 Jun 2012 | 7:17 PM ET

    Investors are pouring money back into high yield, or junk bonds, as they prepare for a long and winding low interest rate environment, reports CNBC's Kayla Tausche. Ron Kruszewski, Stifel Nicolaus CEO and Jim Iuorio, TJM Institutional Services, discuss April factory orders, the European crisis and the state of the U.S. recession.

  • No Huddle Offense: 'Murky' Markets Ahead     Monday, 4 Jun 2012 | 6:58 PM ET

    Mad Money host Jim Cramer shares his final thoughts of the day.

  • Ariad Pharma CEO on Latest Leukemia Data     Monday, 4 Jun 2012 | 6:45 PM ET

    Mad Money host Jim Cramer and Harvey Berger, Ariad Pharmaceuticals chairman/CEO, discuss the state of the health care sector and Ariad's recent research for Sarcoma, Leukemia and other cancers.

  • Mad Money host Jim Cramer discusses why the Fed should not be buying and why the Treasury Department should be selling.

  • Daniel Junius, ImmunoGen chairman/CEO, discusses the latest developments in therapeutics for the treatment of cancer.

  • Cramer Rounds Up Market Weakness     Monday, 4 Jun 2012 | 6:00 PM ET

    Mad Money host Jim Cramer explains why the market is worse off than where it stood in August and October of 2011, but not even close to a 2009 scenario.

  • Trade of the Day: AutoNation     Monday, 4 Jun 2012 | 5:55 PM ET

    The Fast Money traders discuss how an increase in new vehicle sales year-over-year could positively impact AutoNation.

  • Raymond James Downgrades Yum Brands     Monday, 4 Jun 2012 | 5:40 PM ET

    Raymond James has downgraded Yum Brands to "market perform" from "outperform." The Fast Money traders and Scott Nations, NationsShares, offer insight.

  • Beware Europe Tape Bombs in June     Monday, 4 Jun 2012 | 5:40 PM ET

    May was a tough month around the globe and the MSCI All World Index is down more than 9%. The Fast Money traders discuss how the European crisis could impact the markets in June.

  • Managing Losses With a Portfolio Pro     Monday, 4 Jun 2012 | 5:30 PM ET

    The Fast Money traders discuss the trade on Priceline amid its decline; and even portfolio pros are feeling the heat from the volatility in the markets, with Whitney Tilson, T2 Partners founder. Scott Nations, NationsShares, also weighs in on the trade in financials.

  • Shawn Reynolds, Van Eck Global Hard Assets Fund, explains why he is betting on oil E&P stocks.

  • Starbucks' Bread Purchase, What's Next?     Monday, 4 Jun 2012 | 5:15 PM ET

    Starbucks is continuing its expansion beyond coffee and has acquired La Boulange Bakery brand. Nicole Miller Regan, Piper Jaffray analyst and CNBC's Herb Greenberg, offer insight.

  • The Contrarian: Further QE?     Monday, 4 Jun 2012 | 5:10 PM ET

    Dennis Gartman, The Gartman Letter and CNBC's Ron Insana share perspective on whether central banks can save the markets with further quantitative easing.

  • Can Bernanke & the Fed Save the Day?     Monday, 4 Jun 2012 | 5:07 PM ET

    The Fast Money traders and Dennis Gartman, The Gartman Letter, discuss the ongoing weakness in the markets and whether further QE from the Fed could help.

  • Onyx Pharma CEO on New Cancer Drug     Monday, 4 Jun 2012 | 4:40 PM ET

    Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.